What are Lexicon Pharmaceuticals's total assets?

Lexicon Pharmaceuticals (LXRX) holds $268.8M in total assets, down 9.7% year over year.

How much debt does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals carries $57.7M in total debt against $202.9M of shareholders' equity, a debt-to-equity ratio of 0.28.

How much cash does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals holds $67.1M in cash and equivalents.

Can Lexicon Pharmaceuticals cover its short-term obligations?

Its current ratio is 18.79 — current assets exceed current liabilities.

Where does Lexicon Pharmaceuticals's balance sheet data come from?

Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Lexicon Pharmaceuticals LXRX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$63.33M-5.0%	$66.66M+197%	$22.47M-51.5%	$46.35M-27.7%
Short-term investments	$61.9M-63.9%	$171.3M+16.1%	$147.56M+60.4%	$92.01M+306%
Restricted cash	$29M—	$0—	——	——
Accounts receivable, net	$2.38M-31.4%	$3.47M+244%	$1.01M+3,507%	$28K+100%
Inventories	$281K+21.6%	$231K-39.4%	$381K—	$0—
Prepaid expenses and other current assets	$3M-33.8%	$4.53M-11.7%	$5.13M+107%	$2.48M+14.6%
Total current assets	$101.9M-58.6%	$246.19M+39.4%	$176.55M+25.3%	$140.87M+58.4%
Property and equipment, net	$1.86M-25.0%	$2.48M+25.0%	$1.99M-4.1%	$2.07M+76.1%
Accumulated depreciation	$2.71M+29.8%	$2.09M-54.0%	$4.54M+13.9%	$3.98M-17.9%
Operating lease right-of-use assets	10.5%-483,199,989%	483,200,000%-69,200,000%	552,400,000%-88,300,000%	640,700,000%—
Goodwill	$44.54M0.0%	$44.54M0.0%	$44.54M0.0%	$44.54M0.0%
Other non-current assets	$368K0.0%	$368K-55.6%	$828K+101%	$412K-81.8%
Total assets	$184.99M-38.0%	$298.42M+30.1%	$229.43M+18.1%	$194.3M+41.9%
Accounts payable	$3.08M-79.2%	$14.8M+2.9%	$14.39M+38.4%	$10.4M+13.6%
Accrued expenses	$13.19M-56.7%	$30.45M+77.5%	$17.16M+34.3%	$12.78M-1.5%
Current portion of long-term debt	$4.6M—	$0—	——	——
Operating lease liabilities, current	$1.64M+39.7%	$1.18M-9.0%	$1.29M0.0%	$1.29M+18.5%
Total current liabilities	$20.87M-53.9%	$45.25M+43.4%	$31.55M+36.1%	$23.17M+4.7%
Long-term debt	$49.41M-50.7%	$100.3M+0.8%	$99.51M+105%	$48.58M—
Operating lease liabilities, non-current	$6.6M+43.5%	$4.6M-13.2%	$5.3M-2.3%	$5.42M—
Operating Lease Liabilities (Total)	$8.23M+42.6%	$5.78M-11.9%	$6.56M—	——
Other non-current liabilities	$7.17M+3.6%	$6.92M+31.5%	$5.27M-2.9%	$5.42M+356%
Total liabilities	$77.45M-49.2%	$152.47M+11.8%	$136.32M+76.6%	$77.18M+231%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	450M+123,867%	363K+48.2%	245K-99.9%	300M0.0%
Additional paid-in capital	$2.13B+0.6%	$2.12B+13.7%	$1.86B+9.0%	$1.71B+6.2%
Retained earnings	-$2.02B-2.6%	-$1.97B-11.3%	-$1.77B-11.1%	-$1.59B-6.9%
Accumulated other comprehensive income (loss)	$30K-74.8%	$119K+284%	$31K+107%	-$428K-4,180%
Treasury stock	$5.19M+12.4%	$4.62M+60.0%	$2.89M+40.0%	$2.06M-72.6%
Total stockholders' equity	$107.54M-26.3%	$145.95M+56.8%	$93.11M-20.5%	$117.12M+3.1%
Total liabilities and stockholders' equity	$184.99M-38.0%	$298.42M+30.1%	$229.43M+18.1%	$194.3M+41.9%
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$2.5M-80.6%	$12.9M-77.9%	$58.5M—	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	$2.5M-80.6%	$12.9M-77.9%	$58.5M—	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$2.5M-80.6%	$12.9M-77.9%	$58.5M—	——
Available For Sale Securities Debt Securities Current	$61.9M-63.9%	$171.3M+16.1%	$147.56M+60.4%	$92.01M—
Other current assets	$3M-33.8%	$4.53M-11.7%	$5.13M+107%	$2.48M+14.6%
Deferred Tax Assets and Other Non-Current Assets	$368K0.0%	$368K-55.6%	$828K+101%	$412K-81.8%
Net Investment in Lease	$7.32M+51.4%	$4.83M-12.5%	$5.52M-13.8%	$6.41M—
Operating lease right-of-use assets	$7.32M+51.4%	$4.83M-12.5%	$5.52M-13.8%	$6.41M—
Other non-current assets	$368K0.0%	$368K-55.6%	$828K+101%	$412K-81.8%
Property, plant and equipment at cost	$4.57M0.0%	$4.57M-30.0%	$6.53M—	——
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$61.9M-63.9%	$171.3M+16.1%	$147.56M+60.4%	$92.01M+306%
Operating Lease Right-of-Use Assets in Other Assets	$7.32M+51.4%	$4.83M-12.5%	$5.52M-13.8%	$6.41M—
Software and Technology Licenses, Net	$368K0.0%	$368K-55.6%	$828K+101%	$412K-81.8%
Accrued Manufacturing Costs	$6.42M-56.4%	$14.71M+53.4%	$9.59M+22.5%	$7.83M—
Other Commercial Liabilities	$13.19M-56.7%	$30.45M+77.5%	$17.16M+34.3%	$12.78M-1.5%
Accrued Liabilities, Current	$13.19M-56.7%	$30.45M+77.5%	$17.16M+34.3%	$12.78M-1.5%
Compensation and benefits	$6.42M-56.4%	$14.71M+53.4%	$9.59M+22.5%	$7.83M—
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2029 (Lessee)	——	——	——	——
Lease Liability Payments - Due After Year Five	——	——	——	——
Operating Lease Liability Payments - Thereafter (Lessee)	——	——	——	——
Accrued taxes and other expenses	$13.19M-56.7%	$30.45M+77.5%	$17.16M+34.3%	$12.78M-1.5%
Total debt	$62.24M-41.3%	$106.07M0.0%	$106.06M+91.8%	$55.29M+4,978%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	365.8M+0.8%	363M+47.7%	245.8M+29.9%	189.2M+26.1%
Convertible Preferred Stock Authorized Shares	5B0.0%	5B0.0%	5B0.0%	5B+99,900%
Convertible Preferred Stock Issued Shares	2.3M0.0%	2.3M—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$366K+0.8%	$363K+48.2%	$245K+29.6%	$189K+26.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Treasury Stock, Value	$5.19M+12.4%	$4.62M+60.0%	$2.89M+40.0%	$2.06M-72.6%
Preferred Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Cumulative Cost Basis	$4.57M0.0%	$4.57M-30.0%	$6.53M—	——
Accrued research and development services current	$2.93M-76.1%	$12.25M+231%	$3.71M+13.9%	$3.25M-11.4%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$450M0.0%	$450M0.0%	$450M+50.0%	$300M0.0%
Common stock, shares issued (in shares)	$365.85M+0.8%	$363.02M+47.7%	$245.79M+29.9%	$189.21M+26.1%
Common Stock, Shares, Outstanding	$365.85M+0.8%	$363.02M—	——	——
Less than 12 months	$2.5M-80.6%	$12.9M-77.9%	$58.5M—	——
Lessee Operating Lease Liability Payments Due	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.11-0.9%	$0.11+10.4%	$0.10.0%	$0.1—
Other accrued liabilities	$2.2M-4.7%	$2.31M-10.2%	$2.57M+536%	$404K-83.9%
Preferred Stock, Par or Stated Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Preferred Stock, Shares Authorized	$5B0.0%	$5B0.0%	$5B0.0%	$5B+99,900%
Preferred Stock, Shares Issued	$2.3M0.0%	$2.3M—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Restricted cash	$29M—	$0—	——	——
Treasury stock, shares (in shares)	$2.38M+55.9%	$1.53M+76.0%	$867.97K+77.8%	$488.21K—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Lexicon Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Lexicon Pharmaceuticals's total assets?: Lexicon Pharmaceuticals (LXRX) holds $268.8M in total assets, down 9.7% year over year.
How much debt does Lexicon Pharmaceuticals have?: Lexicon Pharmaceuticals carries $57.7M in total debt against $202.9M of shareholders' equity, a debt-to-equity ratio of 0.28.
How much cash does Lexicon Pharmaceuticals have?: Lexicon Pharmaceuticals holds $67.1M in cash and equivalents.
Can Lexicon Pharmaceuticals cover its short-term obligations?: Its current ratio is 18.79 — current assets exceed current liabilities.
Where does Lexicon Pharmaceuticals's balance sheet data come from?: Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.